Agape ATP (ATPC) Competitors

Agape ATP (NASDAQ:ATPC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Do insiders & institutionals have more ownership in ATPC or XGN?

0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 9.7% of Agape ATP shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media refer more to ATPC or XGN?

In the previous week, Exagen had 1 more articles in the media than Agape ATP. MarketBeat recorded 5 mentions for Exagen and 4 mentions for Agape ATP. Agape ATP's average media sentiment score of 0.88 beat Exagen's score of 0.64 indicating that Agape ATP is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agape ATP	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ATPC or XGN?

Agape ATP has a beta of -0.95, suggesting that its share price is 195% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Do analysts prefer ATPC or XGN?

Exagen has a consensus target price of $12.00, suggesting a potential upside of 8.79%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Agape ATP.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agape ATP	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Is ATPC or XGN more profitable?

Exagen has a net margin of -28.85% compared to Agape ATP's net margin of -183.13%. Agape ATP's return on equity of -20.32% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agape ATP	-183.13%	-20.32%	-18.55%
Exagen	-28.85%	-130.38%	-34.69%

Which has stronger valuation and earnings, ATPC or XGN?

Agape ATP has higher earnings, but lower revenue than Exagen. Exagen is trading at a lower price-to-earnings ratio than Agape ATP, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agape ATP	$1.32M	44.93	-$2.47M	-$0.41	-2.89
Exagen	$55.64M	4.36	-$15.11M	-$0.89	-12.39

Summary

Exagen beats Agape ATP on 9 of the 16 factors compared between the two stocks.